GSK's 47% Surge: Is the Pharma Giant Still a Buy After Its Stellar Run?
GSK's shares have soared 47% in the past year, reigniting investor debate. With the stock now trading around £19.46, analysts are divided: do the gains already reflect future promise, or does a deep-value opportunity remain? We examine the key metrics driving the conversation.